[{"orgOrder":0,"company":"Sunovion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dasotraline","moa":"Monoamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Sunovion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sunovion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sunovion Pharmaceuticals \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Dasotraline

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Sunovion has withdrawn the New Drug Applications for dasotraline, a novel dopamine and norepinephrine reuptake inhibitor, for the treatment of moderate-to-severe binge eating disorder (BED) and attention deficit hyperactivity disorder (ADHD).

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 13, 2020

                          Lead Product(s) : Dasotraline

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Dasotraline is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 27, 2017

                          Lead Product(s) : Dasotraline

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Dasotraline is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Binge-Eating Disorder.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 11, 2017

                          Lead Product(s) : Dasotraline

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Dasotraline is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 10, 2016

                          Lead Product(s) : Dasotraline

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Dasotraline is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 12, 2016

                          Lead Product(s) : Dasotraline

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Dasotraline is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Binge-Eating Disorder.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 17, 2016

                          Lead Product(s) : Dasotraline

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Dasotraline is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Binge-Eating Disorder.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 30, 2015

                          Lead Product(s) : Dasotraline

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Dasotraline is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 29, 2015

                          Lead Product(s) : Dasotraline

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Dasotraline is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 28, 2015

                          Lead Product(s) : Dasotraline

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Dasotraline is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Attention Deficit Disorder with Hyperactivity.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          October 28, 2014

                          Lead Product(s) : Dasotraline

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank